Trial · NCT00101192
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
NCT00101192, Phase 2, Completed, Gynecologic Oncology Group; results first posted 2014-03-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer. Trials, record NCT00101192. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00101192
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
- NCT number
- NCT00101192
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 76 participants, actual
- Lead sponsor
- Gynecologic Oncology Group
- Conditions
- Cervical Cancer
- Interventions
- cetuximab, cisplatin
- First posted
- 2005-01-10
- Last updated
- 2014-03-17
- Results first posted
- 2014-03-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Response | up to 6 months from study entry | Per GOG Response Evaluation Criteria In Solid Tumors(RECIST) Criteria: Complete Response(CR): disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial Response(PR): at least a 30% decrease in the sum of longest dimensions(LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of nontarget lesions and no new lesions. Increasing Disease: at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD or the appearance of new lesions within 8 weeks of study entry. Stable Disease: any condition not meeting the above criteria. Indeterminate for response: as having no repeat tumor assessments following initiation of study therapy for reasons unrelated to symptoms or signs of disease. |
| Secondary | Progression-free Survival and Overall Survival at 6 Months After Completion of Treatment | up to 5 years from study entry |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Response | up to 6 months from study entry | Eligible and evaluable participants | participants | NUMBER |
| SECONDARY | Progression-free Survival and Overall Survival at 6 Months After Completion of Treatment | up to 5 years from study entry |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Response | Cetuximab | Complete Response | 1 | participants | |
| Tumor Response | Cetuximab | Partial Response | 7 | participants | |
| Tumor Response | Cetuximab | Increasing Disease | 17 | participants | |
| Tumor Response | Cetuximab | Stable Disease | 34 | participants | |
| Tumor Response | Cetuximab | Indeterminate | 10 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cetuximab | 76 | |
| Overall Study | COMPLETED | Cetuximab | 69 | |
| Overall Study | NOT COMPLETED | Cetuximab | 7 |
Source ClinicalTrials.gov
Adverse events202
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic Reaction/Hypersensitivity | Immune system disorders | Cetuximab | 9 | 69 | |
| other | Otitis Middle Ear | Ear and labyrinth disorders | Cetuximab | 1 | 69 | |
| other | Tinnitus | Ear and labyrinth disorders | Cetuximab | 8 | 69 | |
| other | Hearing (Monitoring Program) | Ear and labyrinth disorders | Cetuximab | 1 | 69 | |
| other | Neutrophils | Blood and lymphatic system disorders | Cetuximab | 13 | 69 | |
| other | Platelets | Blood and lymphatic system disorders | Cetuximab | 13 | 69 | |
| other | Leukocytes | Blood and lymphatic system disorders | Cetuximab | 23 | 69 | |
| other | Hemolysis | Blood and lymphatic system disorders | Cetuximab | 1 | 69 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Cetuximab | 50 | 69 | |
| other | S/N Arrhythmia: Atrial Fibrillation | Cardiac disorders | Cetuximab | 1 | 69 |
1 to 10 of 202Source ClinicalTrials.gov
See all 202 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cetuximab | ||
| Total, other adverse events | Cetuximab | 66 | 69 |
| Total, serious adverse events | Cetuximab | 33 | 69 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21329967 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00101192
GET https://conductscience.org/api/trials/v1/NCT00101192/events?page=2